|Bid||33.02 x 4700|
|Ask||33.03 x 15200|
|Day's Range||32.81 - 33.15|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||27.84|
|Dividend & Yield||1.28 (3.87%)|
|1y Target Est||N/A|
Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.
These brand-name companies offer income and value potential that can't be ignored.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips